AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT05235503
Drug: Medicinal cannabis in combination with oxycodon
RxNorm normalized name: Medical Cannabis
DrugBank: Medical Cannabis (DB14009)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The intervention will be administering the combination of medicinal cannabis in combination with oxycodon
Trial: NCT05235503
Drug: Medicinal cannabis in combination with placebo oxycodon
RxNorm normalized name: Medical Cannabis
DrugBank: Medical Cannabis (DB14009)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The intervention will be administering the combination of medicinal cannabis in combination with placebo oxycodon
Trial: NCT05136196
Drug: Cabozantinib S-malate
RxNorm normalized name: Cabozantinib S-Malate
DrugBank: Cabozantinib (DB08875)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Given PO
Trial: NCT06561698
Drug: Vonoprazan
RxNorm normalized name: vonoprazan
DrugBank: Vonoprazan (DB11739)
FDA approved: no
EMA approved: no
PMDA approved: yes
Description: Potassium competitive acid blocker
Trial: NCT06561698
Drug: Amoxicillin
RxNorm normalized name: Amoxicillin
DrugBank: Amoxicillin (DB01060)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Antibiotics for H. pylori eradication
Trial: NCT06561698
Drug: Bismuth Potassium Citrate
RxNorm normalized name: bismuth
DrugBank: Bismuth cation (DB14572)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gastric mucosal protective drug with anti-H. pylori effect
Trial: NCT05747625
Drug: Zirconium Zr 89 Panitumumab
RxNorm normalized name: Panitumumab
DrugBank: Panitumumab (DB01269)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Given IV
Trial: NCT06072768
Drug: 15-day taper prednisone
RxNorm normalized name: prednisone
DrugBank: Prednisone (DB00635)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The 15-day taper group will assess the effect of an approximately 50% oral prednisone dose reduction over 15 days, and will be followed for an additional 15 days after the last dose reduction.
Trial: NCT06072768
Drug: 150-day taper prednisone
RxNorm normalized name: prednisone
DrugBank: Prednisone (DB00635)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The 150-day taper group will assess the effect of reducing oral prednisone by 1 milligram (mg) every 30 days over 150 days, and will be followed for an additional 30 days after the last dose reduction.
Trial: NCT06242444
Drug: Experimental Dentifrice
RxNorm normalized name: stannous fluoride
DrugBank: Rice (DB10563)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dentifrice containing 1150 ppm fluoride and 5% KNO3.
Trial: NCT06242444
Drug: Placebo Control Dentifrice
DrugBank: Rice (DB10563)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dentifrice containing 0 ppm fluoride and 5% KNO3.
Trial: NCT06242444
Drug: Reference Dentifrice
RxNorm normalized name: stannous fluoride
DrugBank: Rice (DB10563)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dentifrice containing 1100 ppm fluoride as SnF2.
Trial: NCT05567458
Drug: Luspatercept
RxNorm normalized name: Luspatercept
DrugBank: Luspatercept (DB12281)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Specified dose on specified days
Trial: NCT06510309
Drug: Venetoclax
RxNorm normalized name: Venetoclax
DrugBank: Venetoclax (DB11581)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: B-cell lymphoma inhibitor, tablets taken orally per protocol.
Trial: NCT06510309
Drug: Rituximab
RxNorm normalized name: Rituximab
DrugBank: Rituximab (DB00073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Anti-CD20 monoclonal antibody, 10mL or 50 mL single-use vials, via intravenous (into the vein) infusion per protocol.
Trial: NCT05156983
Drug: TAK-330
RxNorm normalized name: TAK-243
DrugBank: TAK-243 (DB15013)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive TAK-330, 25 IU/kg single intravenous infusion on Day 1 and an additional dose of 25 IU/kg TAK-330 can be administered if required.
Trial: NCT04934111
Drug: LNP-nCOV saRNA-02 Vaccine
RxNorm normalized name: LNP-nCoVsaRNA Vaccine
DrugBank: LNP-nCoVsaRNA Vaccine (DB15799)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: a self-amplifying ribonucleic acid (saRNA) vaccine encoding the S glycoprotein of SARS-CoV-2, the causative agent of COVID-19
Trial: NCT05156983
Drug: SOC 4F-PCC
RxNorm normalized name: 4F-PCC
DrugBank: Factor IX Complex (Human) (DB11330)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive 4F-PCC as SOC on Day 1. The dose and infusion speed of the SOC 4F-PCC will be based on local institutional protocols. An additional dose of SOC 4F-PCC not exceeding total dose of 50 IU/kg or 5,000 IU, whichever is smaller can be given during the surgery if required.
Trial: NCT05980091
Drug: Estradiol Valerate 2 MG
RxNorm normalized name: estradiol valerate 2 MG
DrugBank: Estradiol valerate (DB13956)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Participants will commence estradiol valerate 4 mg ( 2 x 2 mg) on day 2 / day 3 of menses.~Estradiol will be increased to 6 mg on day 2 of estrogen treatment, and continued at a daily dose of 6 mg (3 tablets daily)
Trial: NCT05980091
Drug: Progesterone 100 Mg Vaginal Insert
RxNorm normalized name: progesterone 100 MG Vaginal Insert
DrugBank: Progesterone (DB00396)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: The initial progesterone dose of 100 mg will be commenced at 13hrs and repeated at 21hrs considered day 1 (vaginal suppository) when an optimal endometrial thickness for each participant has been achieved with a trilaminar appearance. The following day (day 2) progesterone administration will be increased to 100 mg vaginally three times daily
Trial: NCT05184335
Drug: Brilaroxazine
RxNorm normalized name: Brilaroxazine
DrugBank: Brilaroxazine (DB09226)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RP5063, a new chemical entity (NCE), is a novel multimodal neuromodulator intended for treating schizophrenia and comorbid conditions. This drug is an investigational drug and has not been approved for treatment or marketing. RP5063 belongs to a class of third generation antipsychotics called Dopamine-Serotonin System Stabilizers. The chemical name of the RP5063 active pharmaceutical ingredient (API) is 6-(4-(4-(2,3-dichlorophenyl)-piperazin-1-yl)-butoxy)-2H-benzo\[b\]\[1,4\]oxazin-3(4H)-one hydrochloride.
Trial: NCT06475846
Drug: Ondansetron
RxNorm normalized name: Ondansetron
DrugBank: Ondansetron (DB00904)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ondansetron
Trial: NCT06475846
Drug: blank preparation
RxNorm normalized name: black pepper preparation
DrugBank: Black pepper (DB10557)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: blank preparation.
Trial: NCT00189696
Drug: YM060
RxNorm normalized name: Atorvastatin
DrugBank: Atorvastatin (DB01076)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT04985942
Drug: Lumateperone
RxNorm normalized name: Lumateperone
DrugBank: Lumateperone (DB06077)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lumateperone 42 mg capsules administered orally, once daily.
Trial: NCT05351398
Drug: PDO group
RxNorm normalized name: Padimate O
DrugBank: Padimate O (DB11570)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients with stage III gastric cancer who need neoadjuvant chemotherapy before radical surgery are recruited. And they are treated with individualized neoadjuvant therapy under the guidance of a patient-derived organoid (PDO)-based drug sensitivity assay.
Trial: NCT06532565
Drug: GS-2121
RxNorm normalized name: GS 9137
DrugBank: Elvitegravir (DB09101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Tablet administered orally
Trial: NCT06532565
Drug: Zimberelimab
RxNorm normalized name: Zimberelimab
DrugBank: Zimberelimab (DB17505)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered intravenously
Trial: NCT04988074
Drug: Cemiplimab
RxNorm normalized name: CEMIPLIMAB
DrugBank: Cemiplimab (DB14707)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Cemiplimab for 9 weeks +/- Carboplatin + Paclitaxel
Trial: NCT05575505
Drug: Pentoxifylline 400 MG
RxNorm normalized name: pentoxifylline 400 MG
DrugBank: Pentoxifylline (DB00806)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pentoxifylline (PTX) is a methyl-xanthine derivative that possesses antioxidant and anti-inflammatory characteristics
Trial: NCT05138250
Drug: Mepolizumab 100 MG
RxNorm normalized name: mepolizumab 100 MG
DrugBank: Mepolizumab (DB06612)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: participants will receive 100mg of mepolizumab every 4 weeks for 52 weeks
Trial: NCT05620238
Drug: Carfilzomib
RxNorm normalized name: Carfilzomib
DrugBank: Carfilzomib (DB08889)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Investigate the home administration of Carfilzomib IV reported by both patients and health care staff compared to the hospital setting.
Trial: NCT05580562
Drug: Dordaviprone (ONC201)
RxNorm normalized name: Dordaviprone
DrugBank: Dordaviprone (DB14844)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants ≥ 52.5 kg will receive 625 mg of ONC201 (5 × 125-mg capsules) dosing days; participants \< 52.5 kg will receive a dose (and corresponding number of capsules) scaled by body weight and rounded to 125-mg increments.
Trial: NCT05159427
Drug: Glipizide ER 5 MG 24 HR Extended Release Oral Tablet
RxNorm normalized name: glipizide ER 5 MG 24 HR Extended Release Oral Tablet
DrugBank: Glipizide (DB01067)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Participants are randomized to take one tablet of this study drug by mouth.
Trial: NCT06419673
Drug: Serplulimab
RxNorm normalized name: Serplulimab
DrugBank: Serplulimab (DB17451)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Serplulimab will be administered by intravenous infusion at a dose of 300mg on Day 1 of each 21-day cycle until unacceptable toxicity or loss of clinical benefit as determined by the investigator.
Trial: NCT06419673
Drug: Cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: IV infusion
Trial: NCT05159427
Drug: Rifaximin 200Mg Tab
RxNorm normalized name: RIFAXIMIN 200MG TAB
DrugBank: Rifaximin (DB01220)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Participants will take one tablet of this study drug by mouth.
Trial: NCT05159427
Drug: 13C6-Glipizide
RxNorm normalized name: Glipizide
DrugBank: Glipizide (DB01067)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Participants will take 1 mg of this study drug dissolved in 40 ml glucose solution by mouth.
Trial: NCT06205420
Drug: Injectable composite resin restoration
RxNorm normalized name: Benzoin resin
DrugBank: Benzoin resin (DB11222)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The teeth affected with enamel hypoplasia will be prepared by removing all defective enamel to place the restorations on sound tooth structure as recommended by the IAPD.~A tooth-by-tooth approach will be employed, where adjacent teeth will be isolated with Teflon tape before selective enamel etching. Selective etching of cut enamel will be done for 15 seconds using 37% phosphoric acid gel. Self-etch adhesive system will be used and highly filled flowable composite will be injected in the accurately positioned transparent clear stent through the small channels created by the tip of the restoration syringe in the incisal edge to restore the affected teeth.~Curing will be done on the incisal and labial aspects for 20 seconds and will be repeated after clear stent removal for additional 20 seconds. After removal of the clear stent from the patient's mouth, the restoration sprue as well as excess polymerized restoration will be scrapped off with a scalpel.
Trial: NCT06419673
Drug: Carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: IV infusion
Trial: NCT05347082
Drug: Cholecalciferol
RxNorm normalized name: Cholecalciferol
DrugBank: Cholecalciferol (DB00169)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablets of 4000 IU
Trial: NCT06523517
Drug: Eliglustat Tartrate Capsules
RxNorm normalized name: Eliglustat
DrugBank: Eliglustat (DB09039)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: The initial dose is 42 mg taken orally twice a day. After 2 weeks of treatment, if the blood trough concentration is less than 5 ng/mL, the dose will be increased to 84 mg taken orally twice daily.
Trial: NCT06636123
Drug: Investigational Agent Administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: GZ17-6.02 will be taken orally with a high-fat meal at a fixed dose of 375 mg twice daily each day of a 28-day cycle, continuing until progression or intolerable toxicity
Trial: NCT06635538
Drug: Corifollitropin alfa (CFA) 150 mcg + Clomiphene Citrate (CC) 100 mg/day from D1
DrugBank: Follitropin (DB00066)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: On day 2 or 3 of the menstrual cycle or after 5 days of pill-free interval, a single injection of 150 mcg of CFA (Stimulation Day 1) will be administered.
Trial: NCT04961619
Drug: dabrafenib
RxNorm normalized name: Dabrafenib
DrugBank: Dabrafenib (DB08912)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: There is no treatment allocation. Patients administered dabrafenib by prescription that have started before inclusion of the patient into the study will be enrolled.
Trial: NCT04961619
Drug: trametinib
RxNorm normalized name: Trametinib
DrugBank: Trametinib (DB08911)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: There is no treatment allocation. Patients administered trametinib by prescription that have started before inclusion of the patient into the study will be enrolled.
Trial: NCT06104618
Drug: Enfortumab Vedotin
RxNorm normalized name: ENFORTUMAB VEDOTIN
DrugBank: Enfortumab vedotin (DB13007)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT04955470
Drug: Ketamine Injectable Solution
RxNorm normalized name: ketamine Injectable Solution
DrugBank: Ketamine (DB01221)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: A 10 mg/mL solution of ketamine will be infused over a 40 minute period at a dose of 0.05mg/kg.
Trial: NCT04955470
Drug: Midazolam Injectable Solution
RxNorm normalized name: midazolam Injectable Solution
DrugBank: Midazolam (DB00683)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: A 5 mg/mL solution of midazolam will be infused over a 40 minute period at a dose of 0.02 mg/kg.
Trial: NCT05831566
Drug: Budesonide/Formoterol fumarate dihydrate
DrugBank: Formoterol (DB00983)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: The Digihaler will measure use of inhalation medication and inhaler technique and will give feedback and reminders. The aim is to improve adherence en inhaler technique. The device/medicinal product will be used for 12 months.~It will be used in both groups, but patients in the intervention group are not able to see their own results and will not receive feedback/reminders.
Trial: NCT04431726
Drug: Emicizumab
RxNorm normalized name: Emicizumab
DrugBank: Emicizumab (DB13923)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Initially, all participants will receive 4 loading doses of 3 milligrams per kilogram (mg/kg) emicizumab subcutaneously (SC) once every week (QW) for 4 weeks followed by the maintenance dosing regimen 3 mg/kg emicizumab SC once every 2 weeks (Q2W) for a total of 52 weeks. Starting from Week 17 of treatment, individual participants may have their dose up-titrated to 3 mg/kg SC QW if they experience suboptimal bleeding control.~At the Week 53 clinic visit following consultation with the treating physician, parents/caregivers may elect for their child to continue with the maintenance 3-mg/kg SC Q2W dosing regimen or to switch to the maintenance 1.5-mg/kg SC QW or 6-mg/kg SC once every 4 weeks (Q4W) dosing regimen for the subsequent 7-year long-term follow-up period.~During the study, participants will be treated with emicizumab until unacceptable toxicity, discontinuation from the study due to any cause, or other criteria specified in the protocol, whichever occurs first.
Trial: NCT06412068
Drug: Combined anti-PD-1 and R-CHOP
RxNorm normalized name: Anti-PD-1 monoclonal antibody MGA012
DrugBank: Retifanlimab (DB15766)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sintilimab,200mg, d1, intravenous drip; Rituximab,375mg／㎡, d1,intravenous drip; Cyclophosphamide,750mg／㎡,d2,intravenous drip; Doxorubicin,50mg／㎡ （or Liposome doxorubicin ，40 mg／㎡）,d2,intravenous drip; Vincristine,1.4mg／㎡, d2（Maximum dose 2mg),intravenous drip; Prednisone, 60mg/ m2 , d1-d5,oral administration.
Trial: NCT06634875
Drug: isunakinra
RxNorm normalized name: Isunakinra
DrugBank: Isunakinra (DB12373)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isunakinra is a potent IL1R1 inhibitor
Trial: NCT06451159
Drug: Chemotherapy: fludarabine (FLU)
DrugBank: Fludarabine (DB01073)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive one 3-day cycle of lymphodepletion with FLU 30 mg/m2 prior to administration of KYV-101.
Trial: NCT06635785
Drug: AI-081
RxNorm normalized name: AI-128
DrugBank: AI-128 (DB05841)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AI-081 is a humanized monoclonal antibody targeting PD-1 and VEGF.
Trial: NCT05777603
Drug: aerosolized aztreonam
RxNorm normalized name: Aztreonam
DrugBank: Aztreonam (DB00355)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: antibiotic with gram-negative bacteria coverage
Trial: NCT05777603
Drug: aerosolized vancomycin
RxNorm normalized name: Vancomycin
DrugBank: Vancomycin (DB00512)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: antibiotic with gram-positive bacteria coverage
Trial: NCT05777603
Drug: pembrolizumab
RxNorm normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: standard of care therapy/monoclonal antibody for patients with advanced NSCLC
Trial: NCT04768829
Drug: Moringa oleifera leaf 10mg/100ml
RxNorm normalized name: Moringa oleifera leaf oil
DrugBank: Moringa oleifera leaf (DB14362)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ear drops
Trial: NCT04768829
Drug: Ear Drop
RxNorm normalized name: Ear Drops
DrugBank: Carbamide peroxide (DB11129)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: plain ear drop formulation without moringa
Trial: NCT06168227
Drug: Disitamb Vedotin
RxNorm normalized name: Brentuximab Vedotin
DrugBank: Brentuximab vedotin (DB08870)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: RC48-ADC based therapy
Trial: NCT05364515
Drug: Clobetasol Propionate
RxNorm normalized name: Clobetasol Propionate
DrugBank: Clobetasol propionate (DB01013)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 0.05 propionate clobetasol: daily (first month), alternate (second moth), twice per week (from third month)
Trial: NCT05961644
Drug: Cladribine Subcutaneous Injection
RxNorm normalized name: Cladribine
DrugBank: Cladribine (DB00242)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cladribine subcutaneous injection, 10 mg daily, for 2-3 consecutive days (depending on individual dose)
Trial: NCT04385082
Drug: Active Cannabis
RxNorm normalized name: Medical Cannabis
DrugBank: Medical Cannabis (DB14009)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Smoked cannabis with THC
Trial: NCT04385082
Drug: Placebo Cannabis
RxNorm normalized name: Medical Cannabis
DrugBank: Medical Cannabis (DB14009)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo smoked cannabis (no THC)
Trial: NCT05411237
Drug: Paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: PTX 100 mg/m2 on Day 1 of every 21-day cycle
Trial: NCT06629597
Drug: YL201
RxNorm normalized name: Lasmiditan
DrugBank: Lasmiditan (DB11732)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: YL201 will be administered intravenously on Day 1 of each 3-week cycle at RP3D dose level.
Trial: NCT06629597
Drug: Docetaxel
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Docetaxel will be administered intravenously at 75 mg/m2 on Day 1 of each 3-week cycle.
Trial: NCT06629597
Drug: Gemcitabine
RxNorm normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Gemcitabine will be administered intravenously at 1000 mg/m2 on Day 1 and 8 of each 3-week cycle
Trial: NCT06365437
Drug: Tacrolimus (TAC)
RxNorm normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Standard of Care Concomitant Immunosuppression
Trial: NCT06365437
Drug: Mycophenolate Mofetil (MMF)
RxNorm normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Standard of Care Concomitant Immunosuppression
Trial: NCT06365437
Drug: ATG
RxNorm normalized name: eATG
DrugBank: Antilymphocyte immunoglobulin (horse) (DB09312)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard of Care induction therapy in solid organ transplantation
Trial: NCT06254807
Drug: CT-0525
RxNorm normalized name: CT-179
DrugBank: CT-179 (DB17114)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Autologous monocyte engineered to contain an anti-HER2 chimeric antigen receptor
Trial: NCT06085729
Drug: ADI-PEG 20
RxNorm normalized name: ADI-PEG 20
DrugBank: Pegargiminase (DB06592)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given by Injection
Trial: NCT06085729
Drug: Cabazitaxel
RxNorm normalized name: Cabazitaxel
DrugBank: Cabazitaxel (DB06772)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given by IV (vein)
Trial: NCT06085729
Drug: Carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given by IV (vein)
Trial: NCT04960618
Drug: Gemcitabine
RxNorm normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Participants will receive gemcitabine 1000 mg/m2 on days 1 and 8 on 21-days cycles for up to 6 cycles
Trial: NCT04960618
Drug: Pembrolizumab
RxNorm normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Pembrolizumab 200 mg will be introduced with cycle 2 and will be given on day 1 of each 21-day cycle for up to 35 cycles
Trial: NCT05896228
Drug: Iberdomide
RxNorm normalized name: Iberdomide
DrugBank: Iberdomide (DB12101)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive Iberdomide (Iber) therapy orally (PO) in capsules as follows:~* Combination therapy: Cycles 1 to 8: 1 mg per day\*, Days 1 to 21 every 28 days.~* Monotherapy: Cycles 9 to 20: 1 mg per day\*, Days 1 to 21 every 28 days.~(\*) The first 6 patients will begin at 1 mg/day as lead-in with option to increase to 1.3 mg with dose-escalation cohort after two (2) cycles tolerated therapy